There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tandem Diabetes Care (TNDM – Research Report) and Eli Lilly & Co (LLY – Research Report) with bullish sentiments.
Tandem Diabetes Care (TNDM)
Tandem Diabetes Care received a Buy rating and a $45.00 price target from Leerink Partners analyst Mike Kratky on April 30. The company’s shares closed last Wednesday at $36.20.
According to TipRanks.com, Kratky is a 4-star analyst with an average return of
Tandem Diabetes Care has an analyst consensus of Moderate Buy, with a price target consensus of $38.09, which is a 5.4% upside from current levels. In a report issued on April 29, Wells Fargo also upgraded the stock to Buy with a $45.00 price target.
See the top stocks recommended by analysts >>
Eli Lilly & Co (LLY)
In a report released yesterday, David Risinger from Leerink Partners maintained a Buy rating on Eli Lilly & Co, with a price target of $901.00. The company’s shares closed last Wednesday at $776.75, close to its 52-week high of $800.78.
According to TipRanks.com, Risinger is a 5-star analyst with an average return of
Eli Lilly & Co has an analyst consensus of Strong Buy, with a price target consensus of $882.06, representing a 13.9% upside. In a report issued on April 17, BMO Capital also initiated coverage with a Buy rating on the stock with a $900.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on TNDM:
- Wells upgrades Tandem Diabetes on positive endocrinologist survey
- Tandem Diabetes upgraded to Overweight from Equal Weight at Wells Fargo
- Leerink upgrades Tandem Diabetes to Outperform on attractive risk/reward setup
- Tandem Diabetes upgraded to Outperform from Market Perform at Leerink
- Tandem Diabetes price target raised to $40 from $37 at Stifel
